New Alzheimer’s Discovery Could Change How Scientists Fight the Disease

Key Points:

• Researchers at ETH Zurich have identified the protein GRK2 as a novel contributor to Alzheimer’s disease, discovering that its inactive form aggregates on mitochondria, disrupting energy production and promoting neurodegeneration.
• The team developed an experimental compound, “Compound 10,” which prevents GRK2 aggregation, thereby preserving mitochondrial function, reducing amyloid beta levels, slowing nerve cell loss, and extending survival in mouse models.
• This compound acts upstream of amyloid plaque formation, interrupting a harmful feedback loop between inactive GRK2 and amyloid beta, and also showed unexpected benefits in improving heart function and signs of healthier aging in treated mice.
• The findings highlight mitochondrial dysfunction and cellular stress as critical factors in Alzheimer’s pathology, suggesting that therapies targeting GRK2 could offer a new avenue beyond traditional approaches focused solely on protein deposits.
• While still in early stages, the research team has patented Compound 10 and seeks industry partners to advance it through drug development, aiming to provide a complementary treatment that could improve quality of life for Alzheimer’s patients.